#United States #New York #Class Action #ESSA Pharma #EPIX

ESSA Pharma Inc. Class Action Lawsuit Notification

Investors in ESSA Pharma Inc. (NASDAQ: EPIX) are urged to take immediate action regarding a pending class action lawsuit initiated by The Gross Law Firm. The firm has officially announced that shareholders who purchased EPIX shares between December 12, 2023, and October 31, 2024, can begin the process of registering to participate in this class action. Those interested must pay attention to the approaching deadline of March 25, 2025, by which time lead plaintiff applications must be submitted.

What Are the Allegations?

The lawsuit presents serious allegations against ESSA Pharma's executives concerning misleading statements related to the performance and effectiveness of its drug candidates. The complaint outlines that during the specified class period, ESSA allegedly:
1. Misrepresented the efficacy of masofaniten in combination with enzalutamide, claiming it had significant benefits which were unfounded.
2. Failed to disclose that the combination treatment’s efficacy was less than what was presented to investors, particularly in its use for treating prostate cancer.
3. Suggested that the M-E Combination Study was likely to succeed, despite it being likely to fall short of its primary endpoint.

Due to these allegations, shareholders are encouraged to assess their investment losses and consider joining the class action to seek recovery for the alleged damages incurred as a result of these misleading practices.

Why Should Shareholders Act Now?

The Gross Law Firm emphasizes the necessity for affected shareholders to act quickly and get registered in order to secure their involvement in the case. Moreover, by registering, shareholders will receive important updates regarding the legal process and their rights. Participation in the lawsuit does not necessitate being appointed as a lead plaintiff, providing an accessible path for all investors impacted by the alleged misconduct.

The Next Steps for Shareholders

To register for the class action, shareholders can visit the official notice at the Gross Law Firm's website. Those who complete the registration will also gain access to a portfolio monitoring tool that will provide regular updates about the case.

Moving swiftly is crucial, as the deadline approaches. No financial obligation is required from the shareholders wishing to participate in this case, ensuring that those affected can receive compensation if the court rules in favor of the plaintiffs.

The Gross Law Firm’s Commitment

The Gross Law Firm is a well-respected entity functioning nationally as a class action law firm dedicated to defending the rights of investors. Their mission centers around supporting individuals impacted by deceitful business practices and ensuring corporate transparency. By striving for recovery for investors wronged by misleading statements or practices, the firm seeks to promote accountability within corporate sectors.

As an investor in ESSA Pharma Inc., understanding the implications of this class action and acting promptly can be pivotal for the protection of your investment rights. For further inquiries or assistance, you may contact The Gross Law Firm directly at 15 West 38th Street, 12th floor, New York, NY 10018, or via phone at (646) 453-8903.

Don’t miss this opportunity to stand up for your rights as an investor and ensure your voice is heard in the ongoing legal proceedings regarding ESSA Pharma Inc. Stay vigilant and proactive during this process.